After the initial testosterone surge from the first leuprolide (GnRH agonist) injection resolves and serum testosterone reaches castrate levels, what symptoms are expected?

Expected Symptoms After Testosterone Surge Resolves and Castrate Levels Are Achieved

Once the initial testosterone flare subsides and castrate levels are reached (typically 3-4 weeks after the first leuprolide injection), patients will experience the chronic adverse effects of sustained hypotestosteronemia, which include hot flashes, sexual dysfunction, fatigue, mood changes, weight gain, and metabolic complications. 1

Timeline of Testosterone Suppression

• Testosterone peaks within the first week after the initial LHRH agonist injection, then falls to baseline or below by the end of week 2 2
• Castrate levels (≤50 ng/dL) are typically achieved by 3-4 weeks, with a median time of approximately 21-22 days 1, 2, 3
• In one study, 96% of patients reached castrate levels within 4 weeks of the initial depot injection 3

Common Symptoms After Castration Is Established

Vasomotor and Physical Symptoms

• Hot flashes occur in approximately 45% of patients and represent the most common adverse effect 1, 3
• Fatigue and lassitude are frequently reported 1
• Weight gain develops due to metabolic changes 1
• Gynecomastia may occur from altered hormone ratios 1

Sexual and Psychological Effects

• Complete loss of libido is expected with castrate testosterone levels 1
• Erectile dysfunction becomes universal 1
• Mood lability and cognitive changes can develop 1

Long-Term Metabolic Complications

• Osteopenia and increased fracture risk emerge with prolonged castration 1
• Hypercholesterolemia and altered lipid profiles develop 1
• Insulin resistance and increased diabetes risk occur 1
• Greater risk for cardiovascular disease has been documented 1

Clinical Monitoring Algorithm

1. Measure testosterone levels every 2-4 weeks initially to confirm achievement of castrate range (<50 ng/dL, ideally <20 ng/dL) 4, 3
2. Screen for osteoporosis according to established guidelines, as bisphosphonate therapy may reduce short-term bone loss 1
3. Monitor cardiovascular risk factors including blood pressure, lipids, and glucose 1
4. Assess for symptomatic adverse effects at each visit, particularly hot flashes, fatigue, and mood changes 1

Important Clinical Pitfalls

• Do not assume all patients achieve adequate suppression: 2-4% of patients may fail to reach castrate levels with standard LHRH agonist therapy 3, 5, 6
• Verify testosterone suppression when PSA rises: Inadequate testosterone suppression should be ruled out before diagnosing castration-resistant disease 6
• The 3-month depot formulations occasionally fail: If testosterone escape occurs, switching to monthly injections may restore adequate suppression 6
• Side effects increase with duration of treatment: The adverse metabolic and physical effects accumulate over time with continuous androgen deprivation 1

Distinction from Acute Flare Symptoms

The symptoms after castration is established differ fundamentally from the acute flare period. During the initial 1-2 week testosterone surge, patients with metastatic disease may experience worsening bone pain, urinary obstruction, or spinal cord compression 2, 4. These acute symptoms resolve once testosterone falls. The chronic symptoms described above then emerge and persist as long as castration is maintained 1.